ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14899170

Pathophysiology of Pre-Eclampsia and Eclampsia: "Bridging Mechanisms to Outcomes"
(Tracing the Roots, Understanding the Impact)

Karra Geetha[1*]; B. Shree Bhavana[2]; Satya Jahnavi P[3]; Orugala Amulya[4]; T. Rama Rao[5]

[1]Associate Professor, Department of Pharmaceutics, CMR College of Pharmacy, Kandlakoya, Medchal, Hyderabad, India
[2,3,4]Department of Pharm. D, CMR College of Pharmacy, Kandlakoya, Medchal, Hyderabad, India
[5]Principal, Department of Pharmaceutical Chemistry, CMR College of Pharmacy, Kandlakoya, Medchal, Hyderabad, India.
Author Institution: CMR College of Pharmacy, Hyderabad, India.

Corresponding Author: Dr. Karra Geetha[1*]

Publication Date: 2025/02/21

Abstract: Preeclampsia and eclampsia are severe pregnancy complications recognized by hypertension, proteinuria and organ failure. Prompt diagnosis and management reduce the risk of complications of the mother and foetus. Soluble fms-like tyrosine kinase 1, soluble endoglinand angiogenic factors are important biochemical indicators of disease progression. Increased soluble fms-like tyrosine kinase 1 and decreased levels of placental growth factor(PIGF) are related to endothelial injury, which explains the causal association to these events, but markers linked to endothelial dysfunction such as platelet activation and placentation such as pregnancy-associated plasma protein A can be utilized for early diagnosis and follow-up in women with preeclampsia. Excess of uric acid pushes the condition to progress. Methods like doppler ultrasonography helps a lot in assessing uterine artery resistance and predicting the development of Preeclampsia. The condition puts mothers at risk for seizures, stroke, organ failure and heamolysis, elevated liver enzymes, low platelet count(HELLP) syndrome, while kids can face problems like restricted development, early delivery, and low oxygen availability. Patients with preeclampsia receive treatment through blood pressure maintenance along with seizure prevention requiring administration of magnesium sulphate. If hypertension becomes severe medical staff treat it with either labetalol or hydralazine or nifedipine or with magnesium sulphate (for seizures). Severe hypertension may be treated with other medications including labetalol, hydralazine, or nifedipine. Preventive measures through low-dose aspirin and calcium supplements hold hope predominantly for groups at lower disease risks while early detection plus proper monitoring and management lead to successful maternal and foetal outcomes. The significance of developing advanced analytical approaches along with preventive practices stands out as fundamental to minimize difficulties which emerge from high-risk maternal situations.

Keywords: *Preeclampsia, Eclampsia, Endothelial Dysfunction, Doppler ultrasonography, Hypertension, Proteinuria, Seizures.*

How to Cite: Karra Geetha; B. Shree Bhavana; Satya Jahnavi P.; Orugala Amulya; T. Rama Rao. (2025). Pathophysiology of Pre-Eclampsia and Eclampsia: "Bridging Mechanisms to Outcomes" (Tracing the Roots, Understanding the Impact). *International Journal of Innovative Science and Research Technology*, 10(2), 221-230. https://doi.org/10.5281/zenodo.14899170.

I. INTRODUCTION

- Overview of Preeclampsia And Eclampsia: Eclampsia and preeclampsia are serious pregnancy problems that increase morbidity and death. The FOGSI's National Eclampsia Registry has been important in measuring humanitarianism and providing clinically relevant guidance that might enhance the administration of healthcare. Several intricate pathogenic processes are now thought to be in charge of this illness, which is appropriately known as GESTOSIS, or abnormal pregnancy. Although many preventative measures have been proposed, only a small number of them have been shown to be effective by science. Biomarkers, careful monitoring, evaluation of clinical risk and early prenatal treatment, calcium, nutritional supplements were helpful.

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14899170

Pregnancy-related hypertensive disorders are a confusing and clinically difficult category of problems that contribute significantly to the worldwide consequences of illness in both industrialized and developing nations. Eclampsia and severe preeclampsia cause the deaths of over 72,000 pregnant women annually. That's about two hundred ladies a day. The leading cause of maternal death, after hemorrhage, is preeclampsia-eclampsia.Compared to women in industrialized nations, women in underdeveloped nations are around 300-fold increased risk of death from eclampsia or preeclampsia.Preeclampsia is systemic disorder which is commonly determined by pregnancy-related proteinuria & new-onset hypertension. Serious proteinuria is characterized by presence of 300mg of protein in urine per day. This illness is typified by a broad disease process that may impact several organ systems and inadequate placental perfusion. The varied pathophysiology of cerebral dysrhythmia, which includes aberrant trophoblastic invasion that triggers vasospasm, endothelial failure, and platelet aggregation, makes eclampsia a complicated disease. Worldwide, 5–10% of pregnancies are complicated by hypertension diseases. In Latin America and the Caribbean, hypertensive illnesses cause approximately 25% -pregnancy related death, compared to 9% in Africa and Asia [1].

- Clinical Significance: Preeclampsia and eclampsia are serious hypertension illnesses that cause considerable morbidity and death in pregnant women across the world. Proteinuria and new-onset of hypertension after 20 weeks of gestation phase are indications of preeclampsia, whereas eclampsia is characterized by incidence of convulsions in preeclamptic woman. Obstetrical Complications: Preeclampsia can turn into eclampsia, leading to severe complications such as cerebral hemorrhage, liver and renal failure, and HELLP syndrome. These problems effect the mother's health and can even be life-threatening. Foetal Complications: The syndrome is related with decreased placental perfusion, which causes foetal growth limitation, premature delivery, and higher perinatal death. Early identification and intervention are critical for reducing these negative effects [2].
- Objective of the Review: Preeclampsia and eclampsia reviews aim to provide a full overview of the disorders. They investigate pathogenesis, risk factors, diagnosis, management techniques, which influence on mother and foetal health. In addition, evaluations seek to address advances in research, and the integration of multidisciplinary treatment for better patient outcomes. They also place an emphasis on individualized care techniques and health policy implications [3].

II. PATHOPHYSIOLOGY OF PRE-ECLAMPSIA

Abnormal placentation, which results in placental ischemia and the production of anti-angiogenic proteins such as sFlt-1, is a sign of preeclampsia. Endothelial function is disrupted by this variation between pro- and anti-angiogenic molecules, which results in oxidative stress, inflammation, extensive vasoconstriction [4].

A. Abnormal Placental Development and Spiral Artery Remodelling:

Foetal derived cytotrophoblasts enter and alter the mother's spiral arteries in uterus that guarantee sufficient O2 & nutritional supply for growing uteroplacental unit during a typical pregnancy. Through this intricate process, the small-diameter, greater resistance spiral arteries were transformed to low-resistance, greater capacitance vessels. Poor cytotrophoblast invasion is considered to cause aberrant vascular remodelling and insufficient oxygen supply to the developing uteroplacental unit during preeclampsia. Although the precise processes causing the aberrant vascular remodelling and placental trophoblast invasion in preeclampsia are unknown, several recent research have improved our knowledge of probable pathways that might result in maladaptation [5].

Inadequate functioning of this system may contribute to the pathophysiology of preeclampsia. It has recently been revealed, for example, that local tissue angiotensin-II (Ang II) induces trophoblast invasion in human cells in vitro and in rats in vivo. In a portion of the placenta, tissue Ang II upregulation is an essential growth factor for trophoblast invasion and migration. Through its modulation of activation and development during interaction between cells, the Notch signalling pathway is believed to play a significant role in vasculogenic. Five ligands (DLL1/3/4 and JAG1/2) and four transmembrane receptors (NOTCH1-4) make up the primary route. When receptors and ligands on neighbouring cells engage, the receptor is serially cleaved by proteases, releasing the intracellular domain known as Notch [5].

A recent investigation by Hunkapiller et al. showed that Notch signalling plays a part in vascular remodelling since animals lacking Notch2 have smaller vessels and worse placental perfusion. The discovery that perivascular and endovascular cytotrophoblasts commonly fail to generate the Notch ligand, JAG1, in preeclampsia provides more evidence that pathophysiology of this pregnancy disorder may be significantly influenced by anomalies in Notch signaling. Stork Head Box 1 (STOX1) is a transcription factor that belongs to the winged helix transcription factor family, is another newly identified molecular pathway linked to placental vascular development. Initially, STOX1 was linked to higher frequencies of STOX1 mutation in preeclamptic women, according to an epidemiological investigation. A recent investigation proved that transgenic overexpression-STOX1 in mice results in a phenotype that is similar to preeclampsia in number of important paths, includes proteinuria, elevated maternal circulating levels of soluble endoglin and sFlt-1, and a sharp increase in systolic BP during labor. Even though these findings are exciting, there is still more work to be done to clarify how STOX1 contributes to the development of preeclampsia both causatively and symptomatically [5].

B. Role of Angiogenic and Anti-Angiogenic Factors:

Strong evidence suggests preeclampsia is caused by the variation in proangiogenic and antiangiogenic factors, favouring antiangiogenic agents such sFlt-1. A soluble splice version of VEGF receptor-1 called sFlt-1 can stop

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14899170

proangiogenic substances like VEGF and PlGF from acting in specific tissues. There are more alternatively spliced Flt-1 transcripts. preeclamptic placentas express all mRNA variants approximately three times more than controls, with a modest trend toward sFLT-1_v1. Before preeclampsia is clinically diagnosed, changes in angiogenic variables can be found in females with chronic hypertension who later were diagnosed with superimposed preeclampsia and women who had given birth within 5 to 8 years [5].

C. Endothelial Dysfunction:

Among the numerous vital roles of the vascular endothelium are the stimulation of anticoagulation, antiplatelet, and fibrinolysis processes through the release of various soluble factors, as well as amening smooth muscles by production of vasoconstrictor and vasodilatory chemicals. The variables were activated by placental ischemia in preeclampsia appear to target the maternal vascular endothelium. Recent research showed a significant connection between placental ischemia and vascular function by demonstrating that endothelial-dependent relaxation is attenuated by lower NO synthase function when serum from placental ischemic rats is administered to small mesenteric arteries from normal-pregnant rats. Interestingly, omental arteries of preeclamptic women had higher endothelial adherence and neutrophil infiltration than those from normal pregnant women. The recent studies that aortic endothelial dysfunction and hypertension in pregnant mice are accompanied by a concurrent IL-10 deficit and toll-like receptor activation further highlighted the necessity of appropriate anti-inflammatory pathways in delivery. RUPP rats have decreased action of transcription factor peroxisome proliferator–activated receptor (PPAR-γ). Because endothelial NO synthase is favourably regulated by PPAR-γ and IL-10, malfunctions in these pathways might contribute to the pathophysiology of preeclampsia. During gestation, the new ovarian hormone relaxin promotes Ca2+ efflux from uterine smooth muscle, which subsequently reduces the myogenic tone of renal arteries. Associated to significance of decreased myogenic tone during labor, normal-pregnant sheep's ovine uterine arteries exhibit decreased actin polymerization, while preeclamptic women's omental arteries exhibit increased RhoA kinase expression and action. RhoA kinase promotes actin polymerization and Ca2+ sensitization of the contractile apparatus. It is unclear if the recognized rise of resistance in uterine artery in RUPP is caused by RhoA kinase activation being facilitated by decreased sex hormone control of intracellular Ca2+ [6].

D. Oxidative Stress and Inflammation:

- Inflammatory Pathways Are Induced by Oxidative Stress specifically, the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway is activated by reactive oxygen species produced during placental hypoxia-reperfusion damage. Pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and tumour necrosis factor-alpha (TNF-α) are transcriptionally triggered by NF-κB activation. These cytokines prolong tissue injury and inflammation by further activating leukocytes and endothelial cells.
- Inflammation leads to development of ROS Pro-inflammatory cytokines stimulate immune cells, like macrophages & neutrophils, which serve as major producers of reactive oxygen species. While macrophages contribute to oxidative stress by generating hydrogen peroxide and nitric oxide, activated neutrophils undergo respiratory bursts that produce superoxide radicals.
- The Harmful Cycle While inflammation-driven ROS generation feeds more inflammatory signals, ROS-induced inflammation produces more ROS. This vicious loop makes endothelial dysfunction, placental damage, and systemic complications in preeclampsia [7].

E. Immune System Dysregulation:

- **Lack Of Immune Tolerance In The Mother-Foetus:** Preeclampsia is linked to an imbalance in the immunological tolerance systems that are necessary for a healthy pregnancy. The immunological responses of the mother to foetal antigens are suppressed by regulatory T cells (Tregs) throughout a typical pregnancy. While inflammatory Th17 cells are elevated in preeclampsia, the number of Tregs is decreased. A pro-inflammatory milieu is fostered by this change, which also impairs spiral artery remodelling and causes trophoblast dysfunction [8].
- **Natural Killer Cells (NK) Function:** For proper placental perfusion to be established, uterine natural killer (uNK) cells are necessary. NK cells help trophoblasts invade by producing angiogenic substances. Reduced angiogenic signalling and enhanced cytotoxicity are the results of a changed ratio of activating to inhibitory NK cell receptors in preeclampsia, which exacerbates placental ischemia [9].
- **Proinflammatory Cytokines Elevated:** Pro-inflammatory cytokines like interleukin-6 (IL-6), interferon-gamma (IFN-γ), and tumour necrosis factor-alpha (TNF-α) are elevated in preeclampsia, whereas anti-inflammatory cytokines like interleukin-10 (IL-10) are reduced. This cytokine imbalance contributes to endothelial dysfunction, oxidative stress, and systemic inflammation, all of which are associated with preeclampsia [10].
- **Modified Human Leukocyte Antigen(HLA) Expression:** Trophoblast cells carry unique human leukocyte antigen (HLA) molecules, such as HLA-G, which interact with maternal immune cells to induce immunological tolerance. Preeclampsia causes diminished or aberrant HLA-G expression, resulting in insufficient signalling and immunological rejection of the trophoblast [11].

F. Genetic and Epigenetic Influences:

➢ *Genetic Influences:*

Variations in the maternal, paternal, and foetal genomes confer a genetic propensity to preeclampsia.

- **Maternal Genetic Variants:** Preeclampsia is linked with polymorphisms in genes which stimulate angiogenesis, inflammation, and oxidative stress. For example:

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14899170

- ✓ **FMS-Like Tyrosine Kinase-1 (FLT1):** FLT1 gene variants enhance soluble Flt-1 (sFlt-1), resulting in anti-angiogenic effects and endothelial dysfunction.
- ✓ **Angiotensinogen (AGT):** Polymorphisms in AGT (e.g., M235T) cause hypertension in pregnancy by changing the renin-angiotensin-aldosterone pathway [14].
- **Paternal Genetic Contribution:** The foetus inherits paternal alleles, which regulate trophoblast activity. For example, genes that control human leukocyte antigen (HLA) compatibility between mother and foetus influence maternal immunological tolerance to the placenta [12].

➢ *Foetal Genetic Variants: Genetic Abnormalities in the Placenta, like as Aneuploidies or Particular Mutations, Might Hamper Trophoblast Invasion and Development, Resulting in Preeclampsia [12].*

- *The Impact of Epigenetics:*

Examples of epigenetic alterations include DNA methylation, histone modifications, and non-coding RNA regulation which are necessary for placental development and the mother's response to pregnancy. A dysregulation of these mechanisms results in aberrant gene expression in preeclampsia.

- ✓ **Distorted Deoxyribonucleic Acid(DNA) Methylation:** The processes necessary for trophoblast invasion and angiogenesis are impacted by the hypo- or hypermethylation of important genes.
- ✓ **The H19/IGF2(Insulin-Like Growth Fcator-2) Locus:** Aberrant methylation of this imprinted gene cluster alters growth factor production, limiting placental development.
- ✓ **Placental Soluble Fms-Like Tyrosine Kinase 1(SFLT1):** An anti-angiogenic factor linked to endothelial dysfunction, sFlt-1, is overexpressed when the SFLT1 promoter is hypomethylated [14].
- ✓ **Ribonucleic Acid(RNAS) That Do Not Code:** One factor contributing to trophoblast dysfunction in preeclampsia is dysregulated microRNAs (miRNAs). Preeclampsia, for instance, inhibits trophoblast invasion and mitochondrial function due to an upregulation of miR-210 [13].
- ✓ **Changes In The Histone:** Preeclampsia is triggered by alternations in histone acetylation and methylation, that influence the expression of genes associated with vascular remodelling and immunological tolerance [11].

➢ *How Epigenetic and Genetic Factors Interact:*

Individuals may be predisposed to epigenetic dysregulation due to genetic variations. Gene expression, for instance, can be impacted by changes to miRNA binding sites caused by polymorphisms in the 3′-UTR of certain genes. Similarly, genetic predisposition may combine with epigenetic modifications brought on by environmental variables (such as oxidative stress or hypoxia) to increase the risk of preeclampsia [15].

III. PATHOPHYSIOLOGY OF ECLAMPSIA

It is serious and fatal complication of pregnancy resulting in onset of generalised tonic-clonic seizures in patients with preeclampsia, without any other neurologic conditions. Pathophysiology is concerned with a complex interplay of vascular, neurological, and systemic factors in passing from preeclampsia into an extreme state of neurological dysfunction [16].

➢ *Transition from Preeclampsia to Eclampsia:*

Preeclampsia is determined by hypertension, endothelial dysfunction in systemic circulation, increased permeability of blood vessels, and a pro-inflammatory systemic state. Hypoxia ischemia and placental toxicity appear to be leading mediators of endothelial dysfunction and eventually lead to the production of soluble fms-like tyrosine kinase 1 and sEng, two soluble antiangiogenic factors. This imbalance of angiogenic stimuli causes widespread endothelial damage followed by vasoconstriction. The process of transition from preeclampsia to eclampsia implicates the expansion of such systemic vascular and endothelial abnormalities to CNS. The important factors are:

- **Severe Hypertension:** Sudden, abrupt, and labile hypertension can push the brain's atuoregulatory capacity to the limit, causing hyperperfusion, cerebral edema, and haemorrhage [16].
- **Endothelial Dysfunction:** This makes the permeability of cerebral vessels much higher and disrupts the integrity of blood-brain barrier (BBB) [17].
- **Systemic Inflammation:** An increased inflammatory process adds another layer of insult to vessel wall injury thereby leading to neurogenic dysfunction [18].
- **Disruption Of Coagulation:** The development of microvascular thrombi in the cerebral vasculature, in very severe forms of preeclampsia, may serve to compound ischemia and thus be a candidate for further aggravating the risk for seizure occurrence [19].

➢ *Autoregulation in Cerebral Blood Flow:*

Cerebral autoregulation denotes the capacity that the brain has to sustain blood circulation steady within a varied range of systemic arterial blood pressures. In healthy individuals, this property exists with the given interval of mean arterial pressures, where CPP exists [20].However, in preeclampsia, this autoregulatory capability fails due to the following:

- **Endothelial Dysfunction:** Injury to the endothelium in preeclampsia leads to impaired ability to vasodilate or to constrict appropriately in cerebral vessels [21].
- **Severe hypertension:** Hyperperfusion may combine with bleeding as the rising systolic blood pressure exceeds the autoregulatory threshold [22].

When the mechanisms for autoregulation begin to fail, the cerebral perfusion pressure may produce vasogenic edema (extravasation of plasma into the brain interstitium) and if unchecked, intracerebral hemorrhage. This then puts

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14899170

forth the stage for points of neurological imperative, including seizures [22].

➢ *Disruption of the Blood-Brain Barrier(BBB):*

It is a singularly important structure maintaining brain homeostasis by modulating the movement of pabulum.In preeclampsia & eclampsia, the integrity of the BBB is lost owing to:

- **Injury To Endothelial Cells:** The breakdown of tight junctions between the endothelial cells results from placental antiangiogenic factors, oxidative stress, inflammation.
- **Release Of Cytokines:** A raise in the inflammatory cytokines such as tumor necrosis factor-alpha causes disruption of the BBE.
- **Very High Blood Pressure:** Increased capillary hydrostatic pressure forces plasma components from the intravascular compartment and into the brain tissue.

While this mechanism of BBB disintegration creates a route for fluid accumulation, localized or generalized cerebral edema results. Further elevation of ICP exacerbates neuronal function and hence the onset of seizures [23].

➢ *The Pathogenesis of the Eclamptic Seizure Remains Incompletely Understood, Although Several Factors are Postulated:*

- Cerebral Edema: Cerebral edema, consisting of vacular and cytotoxic edema, is responsible for neural cell swelling and ionic imbalances, resulting in widespread changes in synaptic transmission along wiht heightening the chances of seizure activities [24].
- Oxidative stress: Oxidative stress with enhanced oxidative stress induces the release of excitatory neurotransmitters and hyperexcitability in the CNS [25].
- Neuroinflammation: Primary neuroinflammation due to systemic response e.g. release of cytokines activates glia and further stimulates CNS physiology toward an exaggerated neuronal environment [25].
- Ischemia and Hypoxia: Microvascular thrombi, in addition to some area structures showing ischemia second to impaired cerebral perfusion, can lead to localized neuronal death with consequent release of excitotoxic substances, mostly glutamate [24].

These factors ultimately result in the initiation and spread of seizures. Eclamptic seizures are commonly generalized and associated with extensive cortical and subcortical involvement.

➢ *Eclamptic Seizures Tend To Be The Leading Cause Of Acute Complications, Which In Turn Include (Neurological Complications And Outcome):*

- **Posterior Reversible Encephalopathy Syndrome:** Also called as PRES, this problem refers to that which manifests in vasogenic edema of brain specially,parieto-occipital regions, usually reversible with prompt intervention [26].
- **Cerebral Hemorrhages:** Severe hypertension and autoregulatory dysfunction, and also vascular instability or excitotoxicity, increase the likelihood of ischemic complications likely to do the most significant damage to the residual brain [27].
- **Thromboembolic Cerebrovascular Accident(CVA) :** Microvascular ischemia, then, can lead to the infarction process in any coagulopathic patient [28].

If seizures go untreated, they may subsequently lead to cerebral hypoxia, herniation, and death. Early diagnosis and interventions-such as blood pressure reduction and seizure prevention with magnesium sulfate-are what will save maternal and foetal outcomes [29].

In essence, eclampsia represents the very end of widespread endothelial functional failure, which lead to dysfunction of cerebral autoregulation and in turn BBB damage, compelling cerebral edema and seizures. When it is understood how it carries out its pathophysiological effect, this clarifies the important way in which time-bound interventions can prevent further deterioration and alter the prognosis for maternal and foetal health [30].

IV. MECHANISTIC LINKS TO OUTCOMES IN ECLAMPSIA

It’s a grave condition of preeclampsia characterized by the occurrence of seizures in a pregnant woman with systemic hypertension and multiorgan involvement. Its mechanism behind mechanisms shows direct connections with adverse outcomes pertaining to both mother and fetus. Hypertension, endothelial dysfunction, and systemic inflammation underpin the main mechanism of end-organ injury-leading to maternal and fetal complications.

- **Hypertension And End-Organ Damage:** Hypertension in pre-eclampsia and eclampsia is fundamentally driven by systemic endothelial dysfunction and vasoconstriction. The elevation in blood pressure directs hurt through mechanical stress over blood vessels leading to impairment of perfusion and directly injuring the tissues of about all organ systems [31].
- **Kidney Damage (Acute Kidney Injury, AKI):** Endothelial cell injury within the glomerular capillaries leads to inefficient filtration of plasma. Proteinuria is the result, which is a distinguishing feature of preeclampsia. Prolonged hypertension decreases the blood supply to the kidneys, resulting in ischemia, glomerular swelling (glomerular endotheliosis), and acute tubular necrosis [32].
- **Liver Damage (HELLP Syndrome):** Hypertension with endothelial dysfunction cause microvascular damage in the liver. Increased portal hemorrhage, ischemia, and liver-cell death occur. Hemolysis, elevated liver enzymes, and low platelets (the HELLP syndrome), most frequent findings due to extensive hepatic involvement [31].
- **Cerebral Damage:** Cerebral autoregulation failure results in hyperperfusion, vasogenic edema and BBB opening, causing its own set of neurologic manifestations,

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14899170

such as headache, visual changes, convulsions.Severe hypertension elevates the probability of intracerebral hemorrhage and stroke, major causes of maternal mortality [31].

- **Cardiac and Pulmonary Damage:** Marked hypertension increases cardiac workload, resulting in left ventricular hypertrophy and diastolic dysfunction. Pulmonary edema and other possibilities lie on the surface that is disturbed due to excessive vascular permeability and cardiac dysfunction [33,34].
- **Placental Damage:** The supply of the placenta is reversed or damaged, which causes foetal growth restriction [35].
- **Maternal Complications:** Eclampsia is undoubtedly a major obstacle to maternal health due to its systemic effects on the hypertension, endothelial dysfunction, and the invasion of multiple organs.

A. Neurological Complications:

- **Seizures:** Cerebral edema and ischemia give rise to tonic-clonic seizures that are the hallmark of eclampsia [36].
- **Stroke:** Hypertensive crises can cause either hemorrhagic or ischemic strokes; they are either dead on arrival or have significant and grave lifetime morbidities [37].
- **Posterior Reversible Encephalopathy Syndrome:** Includes vasogenic edema in the parieto-occipital regions causing reversible neurologic deficits that would include changes in mental status, seizures, and visual disturbances [38].

B. Hematological Complications:

- **Heamolysis, Elevated liver enzymes, Low platelet count (HELLP) Syndrome:** A complicated form of pre-eclampsia with hemolysis, liver enzyme elevation, and low platelet count; associated with significant morbidity including liver rupture and disseminated intravascular coagulation (DIC).
- **Coagulopathy:** Microvascular thrombi and platelet consumption both increase the risk of bleeding, inducing organ damage.
- **Renal Failure:** Acute kidney injury is quite common due to glomerular underperfusion, thrombotic microangiopathy, and hypoperfusion.
- **Cardiovascular Complications:** Severe hypertension may lead to myocardial ischemia, heart failure, or pulmonary edema.
- **Death:** Maternal death occurs mainly from cerebral hemorrhage, stroke, or multiple organ failures. Early intervention may provide a very good reduction in mortality rates [39].

➢ *Fetal Complications:*

The fetus is comparatively susceptible to the hemodynamic and vascular perturbations of eclampsia.

- **Fetal Growth Restriction (FGR):** Placental hypoperfusion due to an inadequate remodelling of spiral artery constrains nutrient & O2 supply to fetus and results in intrauterine growth restriction & low birth weight [40].
- **Preterm Birth:** Eclampsia raisons for the delivery to be hurriedly by prior delivery, aimed at adjusting the suffering of the mother and the fetus. Preterm birth carries with it complications like respiratory distress, intraventricular bleeding, and infections, including neonatal sepsis [41].
- **Foetal Hypoxia:** This involves a state where less blood flows to the fetus and thus causes hypoxemia, or low levels of oxygen, which in turn leads to metabolic acidosis and ultimately relates to stillbirth [41].
- **Abruptio Placentae:** The high blood pressure affects the mother leading to higher chances of placental abruption, this syndrome occurs when the placenta separates from the uterine wall before to birth.This results in marked maternal hemorrhage, fetal asphyxia, and stillbirth [42].
- **Perinatal Mortality:** Stillbirth and neonatal death on the high side would be manifest in those pregnancies that have eclampsia as an accompaniment, particularly in the resource-scarce settings [42].

➢ *Integrated Mechanistic Overview:*

- Hypertension is responsible for the major mechanisms of end-organ damage due to inadequate supportive autoregulation of vital organs, such as the brain, kidney, and liver.
- Endothelial Dysfunction enhances vascular permeability and inflammation leading to lesser microvascular damage and systemic complications.
- Central to the pathophysiology and accountable for the maternal syndrome, the placenta forms and releases anti-angiogenic factors and cytokines that lead to systemic and organ damage.

Early assessment and efficacious treatment in preeclampsia & eclampsia include blood pressure control, seizure prophylaxis with magnesium sulfate, and timely delivery. This would significantly reduce these complications and improve the outcome in mother and foetus [43].

V. DIAGNOSTIC BIOMARKERS AND PROGNOSTIC TOOLS

➢ *Biochemical Markers and Imaging and Functional Assessment:*

- **Angiogenic Factors:** Proteinuria and hypertension might result from overabundance of anti-angiogenic growth factors in the blood, particularly sEng & sFlt1.The placenta is the primary source of the endogenous protein sFlt1.VEGF, PGF, and other angiogenic growth factors can be bound by sFlt1 and their effects neutralized. It was shown that soluble endoglin, by causing endothelial cell dysfunction, collaborates with preeclampsia's pathophysiology involving the soluble form of vascular endothelial growth factor receptor 1. A clinical manifestation of preeclampsia was preceded by low levels of free PGF & free VEGF and high levels of sFlt1 in the blood. Reducing preeclampsia-induced morbidity and death would have a major influence on current obstetrical treatment, and assessing soluble fms-like tyrosine kinase

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14899170

1& soluble endoglin in the placental blood flow can be helpful for assessment and testing of preeclampsia [44].

- **Coagulation Factors & Platelets:** Women with moderate hypertension were evaluated for blood uric acid levels, mean platelet volume, and platelet count in order to predict preeclampsia.Lower platelet counts, higher mean platelet volumes, higher plasma concentrations of beta thromoglobulin & platelet 4 in preeclamptic individuals are all indicators of platelet activation. Certain antigens are more often expressed on the surface of preeclamptic individuals throughout the 1st & 2nd trimesters of gestation [44].
- **Uric Acid & Creatinine:** Increased levels of blood uric acid were linked to both perinatal outcomes and the clinical severity of preeclampsia. Hyperuricaemia, an early sign of renal involvement in preeclampsia, is caused by decreased renal clearance from impaired tubular processing of uric acid prior to glomerular conditions, which could result in albuminuria [44].
- **Pregnancy-Associated Plasma Protein A:** Also known as pappalysin 1, insulin-like growth factor binding protein-4 protease, or PAPP-A , is a 400 kDa homodimeric peptidase with 1628 amino acids connected by disulfide bonds. It is mostly found in the maternal blood during pregnancy & compound with proform of pregnancy-associated plasma protein A inhibitor eosinophil major basic protein. The hydrolytic action of PAPP-A is mediated by insulin-like growth factor binding proteins [45].
- **Placental Protein 13(Pp-13):** The 32 kDa dimeric protein known as placental protein 13 (PP13) was initially identified by Bohn et al. in 1983 as originating from the placenta, specifically from the syncytiotrophoblast. Placental tissue exclusively produces PP13, which has a conserved domain for carbohydrates binding to which Annexin-II and Actin-beta bind. These proteins are thought to be crucial for both placenta formation and modification of the mother's arteries,respectively.Delivery causes a progressive rise in PP13 levels.During the first trimester, females who had pre-eclampsia had abnormally low levels of PP13 contrasted to controls. The measurement of serum placental protein 13 during the 1st trimester may be helpful for initial developing of probability of pre-eclampsia, because the levels of placental protein 13 were shown to be elevated throughout all potential groups, including pre-eclampsia, intra uterine growth restriction, premature birth while second & third trimesters [46].
- **A Disintegrin and Metalloprotease:** A protease containing an outer layer that depends on zinc is called a disintegrin and metalloprotease (ADAM12). Numerous pregnancy-related conditions, including preeclampsia, have been reported to exhibit apparent variations in this protease's concentration.Liagaard et al. were the first to link ADAM12 to preeclampsia; their study demonstrated those females with preeclampsia subsequently had reduced levels of ADAM12 in the first trimester [47].
- **Doppler Ultrasonography:** Practical & non-invasive technique for evaluating the hemodynamics of both the mother and the fetus is Doppler ultrasonography. When the myometrial portions of the arteries supplying the spiral arterioles are examined through Doppler flow, increased resistance to vascular flow may be assessed. uterine artery either transvaginal and transabdominal methods are used to perform Doppler ultrasonography. After detecting the uterine artery using color Doppler, pulse-waved Doppler ultrasonography is carried out to collect waveforms from which indices are calculated.The resistance index (RI = S − D/S), pulsatility index (PI = S − D/Vm, where Vm is the mean of maximal velocities throughout the cardiac cycle), systolic to diastolic velocity ratio, and initial diastolic notching belong to the indices. For the purpose of predicting preeclampsia, increases in flow resistance as indicated by pulsatility index or resistance index larger than selected value (>1.45 or 0.58) or percentile (>90th–95th)/existence of unilateral/bilateral diastolic notches were examined [48].

VI. MANAGEMENT STRATEGIES

- Treatment Of Convulsions: The recommended medication for preventing seizures in women with preeclampsia & recurrent convulsions in females having eclampsia is magnesium sulfate. Furthermore, by retaining the BBB & preventing development of cerebral edema, magnesium, calcium antagonist, may influence cerebral endothelium.First-line therapy for eclamptic seizures is magnesium sulfate. MgSo4 is usually a safe medication for pregnant women. IV loading doses of 4 or 6 g should be given over 15 to 20 minutes. After the loading dose, convulsions frequently stop. To avoid repeated seizures, a continuous intravenous solution should be used to deliver maintenance dosage of 1 or 2 g per hour [49].
- Treatment Of Hypertension: Prolonged anticonvulsant treatment is followed by blood pressure management. Preventing ICH & pulmonary edema, are the main causes of death from eclampsia, which are related to hypertension, requires treating severe hypertension (SBP > 160 mmHg and/or DBP ≥ 110 mmHg) following magnesium infusions [49].

An beta-adrenergic & alpha-adrenergic antagonist, labetalol induces vasodilation & decreases pulse rate. To achieve the desired blood pressure, a starting dose of 10–20 mg IV slowly for 2 minutes is recommended, followed by 20–80 mg every 20–30 minutes up to a maximum dose of 300 mg in 24 hours [49].

Hydralazine dilates blood vessels, lowers blood pressure and peripheral vascular resistance.If the SBP is greater than 160 mmHg or the DBP is higher than 110 mmHg, an IV bolus of 5–10 mg over 2 min or 10 mg IM should be administered, followed by 5–10 mg after 20 min, for total dosage of 20 mg IV or 30 mg IM [49].

Nifedipine may be orally taken, especially if an intravenous route was not initiated. One dihydropyridine calcium channel blocker which lowers systemic vascular resistance and encourages vasodilation is nifedipine. The recommended initial dose of immediate-release nifedipine is

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14899170

10 mg, which should be given for every 20 minutes until approximately 180 mg is achieved per day [49].

➢ *Preventive Strategies:*

- Calcium: The incidence of PE and preterm delivery may be significantly reduced by consuming calcium supplements (≥ 1 g/day) during pregnancy, notably for individuals who have a diet containing calcium shortage (< 600 mg/d). Additionally, effectiveness was closely related to timing of consumption, calcium administration during the initial stages of pregnancy may help lower incidence of preeclampsia and pregnancy loss. The incidence of PE was found to be reduced at high doses (1.2 to 2 g/day), medium doses (0.6 to 1.2 g/day), and low doses (< 0.6 g/day) of calcium supplements, according to a recent systemic meta-analysis of 27 randomized trials comprising 28 492 pregnant women. To calculate the optimal calcium dosage for avoiding preeclampsia, additional studies on direct concentration comparisons is recommended [50].
- Aspirin: By preventing platelet aggregation, aspirin was initially utilized to prevent PE. Antiplatelet treatment is prescribed to treat pregnant women with a high risk of PE, regardless of their gestational stage. Aspirin has immunomodulatory, anti-inflammatory, and effects on a range of immune cells.Aspirin suppresses the melanoma-induced natural killer cell activity and the release of cytokines produced from macrophages, including lipopolysaccharide-induced TNF-α and NF-κB. Aspirin also controls dendritic cell maturation and differentiation, which impacts their ability to perform specific functions, such stimulating the proliferation of downstream T cells. Further, aspirin elevates amount of Treg & improves their activity by causing immunological tolerant dendritic cells to express less costimulatory factor and immune tolerant dendritic cells to express more costimulatory factor, which is essential for Treg activation. The probability of proteinuric preeclampsia decreased by eighteen percentage, preterm delivery before 37 weeks by nine percentage, neonatal fatalities/deaths before discharge by fourteen percentage, shorter gestational age, and major unfavorable pregnancy outcomes through the administration of aspirin. A low-dose aspirin treatment is advised by the majority of clinical practice recommendations for pregnant hypertension in order to prevent preeclampsia in high-risk mothers.Presently, four randomized clinical trials have demonstrated that administering aspirin at modest doses can dramatically reduces the risk [50].

VII. CONCLUSION

Eclampsia and preeclampsia are serious pregnancy complications that impact the mother and unborn baby. Abnormalities of the immunological system, reduced oxygen supply to the placenta, including blood vessel problems are associated with these conditions. Elevated oxidative stress, inflammation, and deviations in chemical substances which stimulate blood vessel development are underlying causes of these conditions, which may adversely affect the body's blood vessels. These conditions are triggered by both environmental and genetic factors. Eclampsia is a more severe type of preeclampsia that can lead to potentially fatal consequences. The primary triggers of it comprise extensive inflammation, blood vessel malfunction, and high blood pressure. In order to achieve better outcomes, early identification is necessary since timely intervention with diagnostic tools such as biomarkers may produce a significant impact. Treatment for eclampsia involves magnesium sulfate for seizures and medication for hypertension. Preventive measures including using calcium and aspirin can help lower the occurrence of preeclampsia, particularly in high-risk pregnancies. Further investigation into molecular pathways and biochemical markers holds up the possibility of more effective prevention and treatment. Increased global awareness, early detection, and medical care are required to lower risks and enhance maternal and fetal health.

REFERENCES

[1]. Gupte S, Wagh G. Preeclampsia-eclampsia. J Obstet Gynaecol India. 2014 Feb;64(1):4-13. doi: 10.1007/s13224-014-0502-y. Epub 2014 Jan 31. PMID: 24587599; PMCID: PMC3931898.

[2]. Rana S, Lemoine E, Granger J, Karumanchi SA. Preeclampsia: Pathophysiology, challenges, and perspectives. Circulation Research. 2019 Mar 29;124(7):1094–112.

[3]. Erez, O., Romero, R., Jung, E., Chaemsaithong, P., Bosco, M., Suksai, M., Gallo, D. M., & Gotsch, F. (2022). Preeclampsia and eclampsia: the conceptual evolution of a syndrome. American journal of obstetrics and gynecology, 226(2S), S786–S803. https://doi.org/10.1016/j.ajog.2021.12.001

[4]. Redman, C. W., & Sargent, I. L. (2005). Latest advances in understanding preeclampsia. Science (New York, N.Y.), 308(5728), 1592–1594. https://doi.org/10.1126/science.1111726

[5]. Warrington JP, George EM, Palei AC, Spradley FT, Granger JP. Recent Advances in the Understanding of the Pathophysiology of Preeclampsia. Hypertension. 2013 Oct;62(4):666–73.

[6]. Myatt, L., & Webster, R. P. (2009). Vascular biology of preeclampsia. Journal of Thrombosis and Haemostasis, 7(3), 375-384. doi: 10.1111/j.1538-7836.2009.03304.x

[7]. Redman, C.W., Sargent, I.L., & Staff, A.C. (2021). "Review: The pathogenesis of pre-eclampsia: Development and function of the placenta." *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health*, 25, 100-107. [https://doi.org/10.1016/j.preghy.2021.07.001]

[8]. Williams A, Khan MA, Moniruzzaman M, Rahaman ST, Mannan II, de Graft-Johnson J, Rashid I, Rawlins B. Management of Preeclampsia, Severe Preeclampsia, and Eclampsia at Primary Care Facilities in Bangladesh. Glob Health Sci Pract. 2019 Sep 26;7(3):457-468. doi: 10.9745/GHSP-D-19-00124. PMID: 31527058; PMCID: PMC6816814.

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14899170

[9]. Gamliel M, Goldman-Wohl D, Isaacson B, Gur C, Stein N, Yamin R, et al. Trained Memory of Human Uterine NK Cells Enhances Their Function in Subsequent Pregnancies. Immunity. 2018 May 15 [cited 2023 Apr 2];48(5):951-962.e5. Available from: https://pubmed.ncbi.nlm.nih.gov/29768178/

[10]. Pate AT, Schnell AL, Ennis TA, Samson WK, Gina. Expression and function of nesfatin-1 are altered by stage of the estrous cycle. AJP Regulatory Integrative and Comparative Physiology. 2019 May 29;317(2):R328–36.

[11]. Lee CL, Jan H.W. Veerbeek, Rana TK, Rijn van, Burton GJ, Hong Wa Yung. Role of Endoplasmic Reticulum Stress in Proinflammatory Cytokine–Mediated Inhibition of Trophoblast Invasion in Placenta-Related Complications of Pregnancy. 2019 Feb 1;189(2):467–78.

[12]. Ward K, Hannele Laivuori, Taylor RN. Genetic Factors in the Etiology of Preeclampsia/Eclampsia. Elsevier eBooks. 2022 Jan 1;(Version of Record 14 January 2022.):45–69.

[13]. Williams PJ, Broughton Pipkin F. The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011 Aug;25(4):405-17. doi: 10.1016/j.bpobgyn.2011.02.007. Epub 2011 Mar 22. PMID: 21429808; PMCID: PMC3145161.

[14]. Tiirikainen M, Nityanand A. Understanding the Genetic Origins of Preeclampsia -. LifeDNA. 2024 [cited 2025 Jan 23]. Available from: https://blog.lifedna.com/dna-blog/understanding-the-genetic-origins-of-preeclampsia/

[15]. Tyrmi, J. S., Kaartokallio, T., Lokki, A. I., Jääskeläinen, T., Kortelainen, E., Ruotsalainen, S., Karjalainen, J., Ripatti, S., Kivioja, A., Laisk, T., Kettunen, J., Pouta, A., Kivinen, K., Kajantie, E., Heinonen, S., Kere, J., Laivuori, H., & FINNPEC Study Group, FinnGen Project, and the Estonian Biobank Research Team (2023). Genetic Risk Factors Associated With Preeclampsia and Hypertensive Disorders of Pregnancy. *JAMA cardiology*, *8*(7), 674–683. https://doi.org/10.1001/jamacardio.2023.1312

[16]. Magley M, Hinson MR. Eclampsia. [Updated 2024 Oct 6]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554392/

[17]. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019 Jul 15;366(366):l2381. Available from: https://www.bmj.com/content/366/bmj.l2381

[18]. Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia—Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020 Oct 6;76(14):1690–702.

[19]. Wikipedia Contributors. Eclampsia Wikipedia. Wikimedia Foundation; 2025. Available from: https://en.wikipedia.org/wiki/Eclampsia?utm_source

[20]. Janzarik WG, Ehlers E, Ehmann R, Gerds TA, Schork J, Mayer S, et al. Dynamic Cerebral Autoregulation in Pregnancy and the Risk of Preeclampsia. Hypertension. 2014 Jan;63(1):161–6.

[21]. Maeda KJ, McClung DM, Showmaker KC, Warrington JP, Ryan MJ, Garrett MR, et al. Endothelial cell disruption drives increased blood-brain barrier permeability and cerebral edema in the Dahl SS/jr rat model of superimposed preeclampsia. AJP Heart and Circulatory Physiology. 2020 Dec 4;320(2):H535–48.

[22]. Xiaojuan Liu, Laura A. Graham, Bocheng Jing, Chintan V. Dave, Antihypertensive Deprescribing and Functional Status in VA Long-Term Care Residents With and Without Dementia , Journal of the American Geriatrics Society, (2025).https://doi.org/10.1111/jgs.19342

[23]. Hermes Sandoval, Belén Ibáñez, Moisés Contreras, Felipe Troncoso, Fidel O. Castro, Extracellular Vesicles From Preeclampsia Disrupt the Blood-Brain Barrier by Reducing CLDN5, Arteriosclerosis, Thrombosis, and Vascular Biology, 45, 2, (298-311), (2024)./doi/10.1161/ATVBAHA.124.321077

[24]. Cipolla MJ, Kraig RP. Seizures in Women with Preeclampsia: Mechanisms and Management. Fetal Matern Med Rev. 2011 May;22(2):91-108. doi: 10.1017/S0965539511000040. PMID: 21709815; PMCID: PMC3119563.

[25]. Johnson, Abbie Chapman, "Mechanisms of Seizure during Pregnancy and Preeclampsia" (2015). Graduate College Dissertations and Theses. 336. https://scholarworks.uvm.edu/graddis/336

[26]. Miller EC. Preeclampsia and Cerebrovascular Disease. Hypertension. 2019 Jul;74(1):5-13. doi: 10.1161/HYPERTENSIONAHA.118.11513. Epub 2019 May 6. PMID: 31055951; PMCID: PMC6636840.

[27]. Anna Szyndler, Przemysław Adamski, Kamil Kowalczyk, Dariusz Gąsecki, Cerebrovascular Disease in Preeclampsia, Hypertension and Brain Damage, (253-272), (2024).https://doi.org/10.1007/978-3-031-64928-8_17

[28]. *J Neurocrit Care.* Cerebrovascular complications during pregnancy and postpartum 2019;12 (1): 20-29. 2019 June 25 doi:https://doi.org/10.18700/jnc.190087.

[29]. Vasiliki Katsi, Asimenia Svigkou, Ioanna Dima, Konstantinos Tsioufis, Diagnosis and Treatment of Eclampsia, Journal of Cardiovascular Development and Disease, 11, 9, (257), (2024).https://doi.org/10.3390/jcdd11090257

[30]. Younes ST, Ryan MJ. Pathophysiology of Cerebral Vascular Dysfunction in Pregnancy-Induced Hypertension. Curr Hypertens Rep. 2019 May 23;21(7):52. doi: 10.1007/s11906-019-0961-8. PMID: 31123841; PMCID: PMC6533227.

ISSN No:-2456-2165 https://doi.org/10.5281/zenodo.14899170

[31]. Dulay AT. Preeclampsia and Eclampsia. Merck Manual Professional Edition. Merck Manuals; 2024. Available from: https://www.merckmanuals.com/professional/gynecology-and-obstetrics/antenatal-complications/preeclampsia-and eclampsia?utm_source=chatgpt.com

[32]. Abalos E, Cuesta C, Grosso AL, Chou D, Say L: Global and regional estimates of preeclampsia and eclampsia: a systematic review. *Eur J Obstet Gynecol Reprod Biol* 170(1):1-7, 2013. doi:10.1016/j.ejogrb.2013.05.005

[33]. Vaught AJ, Kovell LC, Szymanski LM, Mayer SA, Seifert SM, Vaidya D, et al. Acute Cardiac Effects of Severe Pre-Eclampsia. Journal of the American College of Cardiology. 2018 Jul;72(1):1–11. Available from: http://www.onlinejacc.org/content/72/1/1.

[34]. Sibai BM, Mabie BC, Harvey CJ, Gonzalez AR. Pulmonary edema in severe preeclampsia-eclampsia: Analysis of thirty-seven consecutive cases. American Journal of Obstetrics & Gynecology. 2025 [cited 2025 Jan 26];156(5):1174–9. Available from: https://www.ajog.org/article/0002-9378(87)90135-9/abstract

[35]. Dengjun Liu, Qian Gao, Yibin Wang, Tao Xiong, Placental dysfunction: The core mechanism for poor neurodevelopmental outcomes in the offspring of preeclampsia pregnancies, Placenta, Volume 126, 2022, Pages 224-232,ISSN 0143-4004, https://doi.org/10.1016/j.placenta.2022.07.014.

[36]. Fishel Bartal M, Sibai BM. Eclampsia in the 21st century. American Journal of Obstetrics and Gynecology. 2020 Sep 24;226(2). Available from: https://www.sciencedirect.com/science/article/pii/S0002937820311285.

[37]. Escudero C, Kupka E, Ibañez B, Sandoval H, Troncoso F, Anna-Karin Wikström, et al. Brain Vascular Dysfunction in Mothers and Their Children Exposed to Preeclampsia. AHA/ASA journals. 2023 Feb 1;80(2):242–56.

[38]. Triplett JD, Kutlubaev MA, Kermode AG, *et al* Posterior reversible encephalopathy syndrome (PRES): diagnosis and management *Practical Neurology* 2022;22:183-189

[39]. Ambad RS, Nandkishor Bankar, Bhatt N, Shrivastava D. To Study the Clinico-Hematological Profile of Pre-Eclampsia on Mother and Newborns. Research Journal of Pharmacy and Technology. 2021 Oct 31;14(10):5527–30.

[40]. Sławek-Szmyt S, Kawka-Paciorkowska K, Ciepłucha A, Lesiak M, Ropacka-Lesiak M. Preeclampsia and Fetal Growth Restriction as Risk Factors of Future Maternal Cardiovascular Disease-A Review. J Clin Med. 2022 Oct 13;11(20):6048. doi: 10.3390/jcm11206048. PMID: 36294369; PMCID: PMC9605579.

[41]. Davies EL, Bell JS, Bhattacharya S. Preeclampsia and preterm delivery: A population-based case-control study. Hypertens Pregnancy. 2016 Nov;35(4):510-519. doi: 10.1080/10641955.2016.1190846. Epub 2016 Jun 20. PMID: 27322489.

[42]. Parker SE, Werler MM, Gissler M, Tikkanen M, Ananth CV. Placental abruption and subsequent risk of pre-eclampsia: a population-based case-control study. Paediatr Perinat Epidemiol. 2015 May;29(3):211-9. doi: 10.1111/ppe.12184. Epub 2015 Mar 11. PMID: 25761509; PMCID: PMC4400232.

[43]. Sharma DD, Chandresh NR, Javed A, Girgis P, Zeeshan M, Fatima SS, Arab TT, Gopidasan S, Daddala VC, Vaghasiya KV, Soofia A, Mylavarapu M. The Management of Preeclampsia: A Comprehensive Review of Current Practices and Future Directions. Cureus. 2024 Jan 2;16(1):e51512. doi: 10.7759/cureus.51512. PMID: 38304688; PMCID: PMC10832549.

[44]. S Kanagasabai. Biochemical Markers In The Prediction Of Pre-Eclampsia, Are We There Yet?. The Internet Journal of Gynecology and Obstetrics. 2009 Volume 14 Number 1.

[45]. Grill, S., Rusterholz, C., Zanetti-Dällenbach, R. *et al.* Potential markers of preeclampsia – a review. *Reprod Biol Endocrinol* 7, 70 (2009). https://doi.org/10.1186/1477-7827-7-70

[46]. Petla, Lakshmi Tanuja; Chikkala, Rosy; Ratnakar, K.S.*; Kodati, Vijayalakshmi**; Sritharan, V.. Biomarkers for the management of pre-eclampsia in pregnant women. The Indian Journal of Medical Research 138(1):p 60-67, July 2013.

[47]. Renad Marwan Alghifari, Nuwayir Ibrahim Alhusayni, Zahrah Fuad Alyamani, Aliaa Sabban, Yousef Almoghrabi, Khalid Hussein Bakheit. The Role of Biochemical Markers in the Prediction of Preeclampsia. International Journal of Biochemistry Research & Review. 2023 Nov 2;32(8):39–47.

[48]. Zhong Y, Tuuli M, Odibo AO. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenatal Diagnosis. 2010;n/a-n/a.

[49]. Katsi V, Asimenia Svigkou, Dima I, Konstantinos Tsioufis. Diagnosis and Treatment of Eclampsia. Journal of Cardiovascular Development and Disease. 2024 Aug 23;11(9):257–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11432638/

[50]. Qi, J., Wu, B., Chen, X. *et al.* Diagnostic biomolecules and combination therapy for pre-eclampsia. *Reprod Biol Endocrinol* 20, 136 (2022). https://doi.org/10.1186/s12958-022-01003-3.